ImmunoCellular Therapeutics, Ltd. (IMUC)
USD 0.17
(0.06%)
USD 0.17
(0.06%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 4.73 Million USD | 36.57% |
| 2022 | 3.46 Million USD | 152.62% |
| 2021 | 1.37 Million USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2001 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 FY | 4.73 Million USD | 36.57% |
| 2022 FY | 3.46 Million USD | 152.62% |
| 2022 Q4 | 3.46 Million USD | 13.71% |
| 2022 Q3 | 3.04 Million USD | 0.0% |
| 2022 Q1 | 2.77 Million USD | -1.46% |
| 2021 FY | 1.37 Million USD | 0.0% |
| 2021 Q3 | 1.2 Million USD | 0.0% |
| 2021 Q1 | - USD | 0.0% |
| 2021 Q4 | 2.81 Million USD | 134.46% |
| 2020 Q4 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 88.507% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -14.879% |
| SQZ Biotechnologies Company | 27.47 Million USD | 82.763% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 89.082% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 84.092% |
| Mesoblast Limited | 118.7 Million USD | 96.011% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -399.36% |
| Genus plc | 233.1 Million USD | 97.969% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -61.592% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -252.437% |
| Marizyme, Inc. | 18.71 Million USD | 74.701% |
| ContraFect Corporation | 2.88 Million USD | -64.362% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -531.371% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -3395.008% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -227.402% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -103.584% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 16.313% |
| MultiCell Technologies, Inc. | 202.58 USD | -2337387.412% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 91.763% |
| EV Biologics, Inc. | 1.49 Million USD | -216.794% |
| Q BioMed Inc. | 4.1 Million USD | -15.214% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 85.694% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -651.54% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -285.496% |
| Biomind Labs Inc. | 735.54 Thousand USD | -543.781% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 97.24% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 63.566% |
| Skye Bioscience, Inc. | 4.61 Million USD | -2.6% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -433.214% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -3246.063% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 19.346% |
| IMV Inc. | 28.88 Million USD | 83.606% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -18311.61% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -109.676% |
| GB Sciences, Inc. | 1.75 Million USD | -169.156% |
| Alpha Cognition Inc. | 1.22 Million USD | -288.02% |
| HST Global, Inc. | 98.31 Thousand USD | -4716.243% |
| CSL Limited | 12.18 Billion USD | 99.961% |
| Halberd Corporation | 150 Thousand USD | -3056.855% |
| Enzolytics Inc. | 996.33 Thousand USD | -375.269% |
| Resverlogix Corp. | 6.49 Million USD | 27.048% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -891.682% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -1752.672% |
| argenx SE | 20 Million USD | 76.324% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 89.606% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -74.817% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -46210.826% |
| Genscript Biotech Corporation | 417.73 Million USD | 98.866% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -2260.371% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -97.491% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -1965.184% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 93.0% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -56.477% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -1216.417% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 76.706% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -3085.439% |
| BioStem Technologies, Inc. | 4.71 Million USD | -0.507% |
| ONE Bio Corp. | 19.71 Million USD | 75.981% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -1792.735% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -1803.861% |
| Agentix Corp. | 50 Thousand USD | -9370.564% |
| LadRx Corporation | 33.6 Thousand USD | -13990.585% |
| Cell Source, Inc. | 9.25 Million USD | 48.831% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -526.191% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -526.191% |
| NovAccess Global Inc. | 2.19 Million USD | -115.252% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 33.049% |
| Itoco Inc. | 228.37 Thousand USD | -1973.45% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -2144.475% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 4.971% |
| Kadimastem Ltd | 891.22 Thousand USD | -431.322% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -1078.373% |
| CytoDyn Inc. | 30.07 Million USD | 84.256% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -877.79% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -1245.836% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 39.446% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -3765.536% |
| Rebus Holdings, Inc. | 310 Thousand USD | -1427.51% |
| International Stem Cell Corporation | 4.17 Million USD | -13.338% |
| Bioxytran, Inc. | 1.92 Million USD | -145.989% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -7487.012% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -117.125% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 43.058% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 44.842% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -204.426% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -1666.896% |
| Neutra Corp. | 54.15 Thousand USD | -8643.781% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -158.759% |
| PureTech Health plc | 25.51 Million USD | 81.439% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -286.798% |
| IXICO plc | 472.02 Thousand USD | -903.189% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 69.452% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 92.395% |
| CSL Limited | 12.18 Billion USD | 99.961% |
| Cellectis S.A. | 92.77 Million USD | 94.896% |